Enabling A Smarter Way for Cell SEPARATION in Personalized CAR-T
SmartSep™ enables a large-scale, fully-automated cell separation and beads depletion solution for seamless integration into today’s complex CAR-T production process.
The CAR-T Personalized Medicine
SmartSep™ SEAMLESSLY INTEGRATES WITHIN THE CAR-T PRODUCTION PROCESS
Today, there is a real industry challenge to produce these personalized cell therapy treatments. Alongside the need for personalized production for each patient, manufacturing processes of engineered T cells are highly complex, making them mini-scale in production, labor intensive and time-limited from sample collection to treatment.
SmartSep™ enables a large-scale, fully-automated cell separation solution for seamless integration within today’s complex CAR-T production process. With over 66% of cell manufacturers selecting magnetic-based cell isolation technologies2, our advanced technology overcomes many cited industry challenges3, including bead removal and loss of final cellular product, to be the leading market solution for cell isolation.
- CAR T Cell Therapy Market 2019 | Scope of Current and Future Industry 2028, 2019.
- Vormittag P, et al. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol. 2018 Oct; 53:164-181.
- Iyer RK, et al. Industrializing Autologous Adoptive Immunotherapies: Manufacturing Advances and Challenges, Front. Med, 23 May 2018.